Abstract: Provided herein are methods, compounds, and compositions for safely reducing thrombopoietin in a cell or an individual. Such methods, compounds, and compositions maintain platelet count within a safe hemostatic range. Such methods, compounds, and compositions are useful to safely treat, prevent, or ameliorate a disease that can benefit from platelet count reduction in an individual. Such methods, compounds, and compositions are useful for treating or preventing diseases in which thrombopoietin contributes to the presence or activation of platelets contributes to and promotes disease initiation or progression, and/or adversely affects disease outcome.

Abstract: Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.

Abstract: The present disclosure provides cytomegalovirus vectors encoding fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, cytomegalovirus vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.

Abstract: Methods of inducing a CD8+ T cell response to a heterologons antigen in which at least 10% of the CD8+ T cells are MHC-E restricted are disclosed. The method involves immunizing with a CMV vector that does not express UL128 and UL130 proteins. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, a UL40 protein, and a US28 protein but that do not express an active UL128 and UL130 protein. Also, disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active UL40 protein, UL128 protein, UL130 protein, and optionally a US28 protein. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active US28 protein, UL128 protein, UL130 protein, and optionally a UL40 protein.

Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.

Abstract: Provided are methods and pharmaceutical combinations utilizing a phospholipase A2 inhibitor for the inhibition of treatment-induced autophagy.

Abstract: Nerve-specific fluorophore formulations for direct or systemic administration are described. The formulations can be used in fluorescence-guided surgery (FGS) to aid in nerve preservation during surgical interventions.

Abstract: A user equipment (UE) registers on a first Public Land Mobile Network (PLMN) and, while in an idle mode, receives a Multimedia Broadcast Multicast Services (MBMS) service. The UE determines whether to perform a periodic network reselection search for a higher priority PLMN while in the idle mode, wherein the UE determines whether to perform the periodic network reselection search based on reception of the MBMS service. The UE may postpone the periodic network reselection search for a period of time while the UE receives the MBMS service in the idle mode. The UE may postpone the periodic network reselection search for a period of time while the UE receives the MBMS service in the idle mode. The UE may interleave the periodic network reselection search with the reception of transmission bursts of the MBMS service, the search being performed on frequencies other than that of the MBMS transmission.

Abstract: The present disclosure provides biomarkers for the detection of coronary artery disease. The biomarkers comprise oxylipins and the detection, identification, and quantification can provide a means to diagnose, prognose, and manage subject at risk for cardiovascular disease. Methods of also provided for the detection and quantification of the oxylipins, for treating, and for predicting the survival of a subject at high risk for coronary artery disease.

Abstract: Surgical clips and surgical applicators used in performing rapid tissue closure in either minimally invasive surgeries or traditional open procedures are provided. In one example approach, a surgical clip comprises opposing sides extending from a top portion and terminating at tips positioned below the top portion. The resting position of the clip is its closed position, and in the closed position, the tips are set at a first distance apart. Each side has a cut-out (or hole or aperture) opposite one another. Each cut-out is fully surrounded by the side and does not extend to the top or tips. Each cut-out is configured to engage an inwardly turned hook at the end of a clip array or clip applicator such that the sides bend outwardly away from each other when pressure is applied on the top portion of the clip, thereby placing the clip in an open position.

Abstract: Disclosed herein are methods and systems for the identification and characterization of perivascular spaces in the cerebral vasculature using magnetic resonance imaging (MRI) data. The disclosed methods allow for automated and unbiased quantification of enlarged perivascular space (ePVS) in a subject, and thus can provide a substantial improvement over manual grading methods used in the art. An example method includes receiving an MRI dataset including voxels having intensity values, identifying a set of candidate voxels within the MRI dataset based on the intensity values; grouping the set of candidate voxels into a set of first clusters; filtering the set of first clusters to generate a set of second clusters; and filtering the set of second clusters based on a morphologic constraint, thereby identifying an enlarged perivascular space in the MRI dataset.

Abstract: Methods, systems, and apparatuses for detecting and describing heterogeneity in a cell sample are disclosed herein. A plurality of fields of view (FOV) are generated for one or more areas of interest (AOI) within an image of the cell sample are generated. Hyperspectral or multispectral data from each FOV is organized into an image stack containing one or more z-layers, with each z-layer containing intensity data for a single marker at each pixel in the FOV. A cluster analysis is applied to the image stacks, wherein the clustering algorithm groups pixels having a similar ratio of detectable marker intensity across layers of the z-axis, thereby generating a plurality of clusters having similar expression patterns.

Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

Abstract: Disclosed herein are synthetic oligoribonucleotides that form hairpin loop structures. The oligoribonucleotides can be used in the treatment of viral infection including prophylactic treatments. The oligoribonucleotides can also be used as adjuvants.

Abstract: Methods and systems for identifying CNV membranes and vasculature in images obtained using noninvasive imaging techniques are described. An example method includes generating, by a first model based on at least one image of a retina of a subject, a membrane mask indicating a location of a CNV membrane in the retina. The method further includes generating, by a second model based on the membrane mask and the at least one image, a vasculature mask of the retina of the subject, the vasculature mask indicating CNV vascularization in the retina.

Abstract: Disclosed herein are methods and systems for optical coherence tomography (OCT) angiography (OCTA). An interleaved scanning pattern is described herein for both raster and bidirectional scanning methods. The interleaved scanning pattern provides B-scans with different scanning intervals. OCTA images based on the B-scans may be combined to obtain a high dynamic range (HDR) OCTA image. Other embodiments may be described and claimed.

Abstract: Devices, systems, reagents, and methods for the performance of multi-spectrum super resolution microscopy are disclosed.

Abstract: Methods are disclosed for correcting a mutant allele of a gene of interest in a primate cell. The methods include a) introducing a non-naturally occurring targeted nuclease and site-specific nucleotide-binding guide that act together to introduce double-stranded breaks in the mutant allele into the primate cell, wherein: i) the primate cell is undergoing mitotic cell division; ii) the primate cell comprises a genome that is heterozygous for the mutant allele, such that the genome comprises one copy of the mutant allele and one copy of a wild-type allele; iii) single-stranded oligonucleotides homologous to the wild-type allele are not introduced into the primate cell. The methods also include b) allowing the primate cell to activate homology-directed repair of the double-stranded DNA breaks in the mutant allele, thereby correcting the mutant allele using the normal wild-type allele as a repair template and producing a primate cell that is homozygous for the wild-type allele.

Abstract: Human cytomegalovirus vectors comprising heterologous antigens are disclosed. The vectors derived from the TR strain, are ganciclovir-sensitive, include active US2, US3, US6, US7 and UL131A genes, and have a deleterious or inactivating mutation in the UL82 gene preventing the expression of pp71.

Abstract: Disclosed are methods of treating colorectal cancer that involve administering a composition comprising an effective amount of miR-451a to cells in the colorectal cancer and further treating the colorectal cancer cells with ionizing radiation. Also disclosed are methods of predicting whether a colorectal cancer in a subject will respond to ionizing radiation. These methods involve measuring the RNA expression of miR-451a, miR-1322, miR-133-3p, miR-1, miR-205-5p, miR-4521, CAB39, EMSY, or MEX3C in the sample and measuring the RNA expression of the same marker in a control.